Sativex faces more delays

The UK's GW Pharma has taken two blows in one day. In a report filed by Agence de Presse Medical, an unnamed regulator said that the biotech had failed in its bid to persuade British regulators to let it go ahead and market the cannabis-based Sativex without further trials. Its stock also went into a tailspin after the US Supreme Court ruled Monday that state laws did not protect marijuana smokers from federal laws banning the substance. GW Pharma had hoped to start selling Sativex in the UK by the end of 2003 but has faced repeated delays in getting it to market.

- read this story from Sharecast

ALSO: Critics contend that it is inconsistent for the Supreme Court to rule that it is legal for doctors to advise patients on using marijuana and then decide that state laws don't protect users. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.